Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Topical pan-JAK inhibitor

Delgocitinib

Brand names: Anzupgo

Delgocitinib is a topical Janus kinase (JAK) inhibitor used for inflammatory skin conditions such as chronic hand eczema.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits the JAK family of enzymes, blocking cytokine-driven JAK-STAT signalling that mediates skin inflammation.

Prescribing in practice

  • As a topical agent applied to limited skin areas systemic exposure is low, but it should still be used in line with its licensed indication and the SPC.
  • Avoid use on skin affected by untreated infection and treat any clinically infected eczema appropriately.
  • Reassess if there is inadequate response after an appropriate treatment period.

Monitoring

Monitoring is principally clinical, assessing improvement in the treated eczema and local tolerability.

Counselling the patient

  • Apply to the affected areas as directed and continue emollients.
  • Tell your clinician if the skin becomes infected or fails to improve.
  • Report any persistent irritation at the application site.

Evidence & guidelines

Delgocitinib's use in chronic hand eczema is supported by its topical JAK-inhibitor clinical trial programme; consult the SPC for licensed details.

Reference: NICE TA evaluation; BAD; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways